REGiMMUNE Receives $12 Million In Grants To Develop Transplant And Allergy Drugs

REGiMMUNE Corporation, a privately held biopharmaceutical company focused on developing technologies and products for immune disorders, today announced that it has received two separate grants totaling more than $12 million from the Japan Science and Technology Agency (JST) and from National Institute of Biomedical Innovation (NIBIO).

More: continued here

Filed under: Allergies on December 15th, 2008